Stock Analiz

Allogene Therapeutics, Inc. ALLO

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026

$0.84Market cap $291M
Open the interactive analysis →

Allogene Therapeutics, Inc. (ALLO) is a healthcare company listed in the US with a market value of about $291M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$174M, a net margin of -3760.0%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -41%.

About Allogene Therapeutics

Allogene Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2018. Revenue went from $114M in 2021 to $3M in 2025, a decline of about 61.1% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 54% over three years (dilution for shareholders). It spends 5775% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S62.6
P/B0.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-37.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)2500.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-165600.0%
ROIC (5-yr avg.)-40.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$5M$3M$100000$95000$156000$114M$0
Net income-$174M-$191M-$258M-$327M-$340M-$182M-$316M
Free cash flow-$109M-$150M-$201M-$239M-$226M-$206M-$181M
EPS (diluted)$-0.61$-0.87$-1.32$-2.09$-2.38$-1.34$-2.63
Net margin-3760.0%-7341.8%-257600.0%-344500.0%-218200.0%-159.6%—
ROIC—-55.7%-42.1%-54.0%-34.5%-18.1%-24.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 9 analysts is $9.00, 973% above the current price; targets range from $4.00 to $14.00; the consensus rating is “Strong buy”; expected EPS is $-0.58 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Allogene Therapeutics pay a dividend?

Not currently.

Is Allogene Therapeutics a good stock to buy?

We do not give buy or sell advice. Allogene Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.